Andrew Stewart Plump net worth and biography

Andrew Plump Biography and Net Worth

Insider of Takeda Pharmaceutical

Andrew Plump, M.D., Ph.D., is the president of Research & Development (R&D) at Takeda and serves as a member of the company’s Board of Directors.

Dr. Plump joined Takeda to oversee the company’s global R&D organization in 2015. Early in his Takeda tenure he orchestrated a multi-year strategic and cultural transformation that resulted in a renewed focus on innovation, streamlined global footprint, prioritized therapeutic areas of focus, a rich network of partnerships and a modality-diverse portfolio of newly approved and promising late-stage development experimental therapies. He also championed efforts to establish an exciting and sustainable early development and research pipeline, founded on strong translational science. Over the last several years of Dr. Plump’s leadership, Takeda has embraced scientific advances and the emergence of data and digital technology to build a renewed, diverse and highly innovative pipeline of investigational medicines that are expected to provide meaningful benefits to patients.

Prior to Takeda, Dr. Plump served as senior vice president, Research & Translational Medicine, deputy to the president of R&D at Sanofi, based in Paris, France. Before Sanofi, he served as vice president, Worldwide Cardiovascular Research head at Merck, where he had direct responsibility for cardiovascular research, preclinical development and translational sciences.

Dr. Plump received his M.D. from the University of California, San Francisco (UCSF), his Ph.D. in cardiovascular genetics with Dr. Jan Breslow at Rockefeller University and his B.S. from the Massachusetts Institute of Technology (MIT). He completed a residency in Internal Medicine and a fellowship in Medical Genetics at UCSF. Following his clinical training, Dr. Plump trained as a Howard Hughes and Stanley J. Sarnoff postdoctoral fellow with Dr. Marc Tessier-Lavigne at UCSF, concurrently assuming faculty responsibilities as an adjunct clinical instructor in the Department of Medical Genetics.

Dr. Plump lives in Boston with his wife Suzanne and has three children.

What is Andrew Stewart Plump's net worth?: The estimated net worth of Andrew Stewart Plump is at least $4.75 million as of August 19th, 2026. Plump owns 261,656 shares of Takeda Pharmaceutical stock worth more than $4,754,290 as of August 21st. This net worth approximation does not reflect any other assets that Plump may own. Learn More about Andrew Stewart Plump's net worth.
How do I contact Andrew Stewart Plump?: The corporate mailing address for Plump and other Takeda Pharmaceutical executives is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. Takeda Pharmaceutical can also be reached via phone at (166) 204-2111 and via email at [email protected]. Learn More on Andrew Stewart Plump's contact information.
Has Andrew Stewart Plump been buying or selling shares of Takeda Pharmaceutical?: Over the course of the past ninety days, Andrew Stewart Plump has sold $3,191,567.29 in shares of Takeda Pharmaceutical stock. Most recently, Andrew Stewart Plump sold 19,651 shares of the business's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $18.49, for a transaction totalling $363,346.99. Following the completion of the sale, the insider now directly owns 261,656 shares of the company's stock, valued at $4,838,019.44. Learn More on Andrew Stewart Plump's trading history.
Who are Takeda Pharmaceutical's active insiders?: Takeda Pharmaceutical's insider roster includes Lauren Duprey (Chief Transformation Officer), Samaan Farajallah (Insider), Anne Furney (General Counsel), Deidre Greenway (Insider), Riad Ibrahim (Insider), Julie Kim (Representative Director – President and CEO), Agosti Pignagnoli (Insider), Giles Platford (President, International Business Unit), Andrew Plump (Insider), Gabriele Ricci (Insider), and Elaine Shannon (President, Global Supply & Quality). Learn More on Takeda Pharmaceutical's active insiders.
Are insiders buying or selling shares of Takeda Pharmaceutical?: During the last twelve months, insiders at the sold shares 13 times. They sold a total of 476,731 shares worth more than $8,192,524.79. The most recent insider tranaction occured on August, 19th when insider Andrew Stewart Plump sold 19,651 shares worth more than $363,346.99. Insiders at Takeda Pharmaceutical own 0.0% of the company. Learn More about insider trades at Takeda Pharmaceutical.
Information on this page was last updated on 8/19/2026.

Andrew Stewart Plump Insider Trading History at Takeda Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/19/2026	Sell	19,651	$18.49	$363,346.99	261,656
8/10/2026	Sell	165,393	$17.10	$2,828,220.30	766,569

Andrew Stewart Plump Buying and Selling Activity at Takeda Pharmaceutical

Takeda Pharmaceutical Company Overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Today's Range

Now: $18.17

$18.08

$18.25

50 Day Range

MA: $16.75

$15.41

$18.37

2 Week Range

Now: $18.17

$12.99

$18.90

Volume

1,479,067 shs

Average Volume

3,162,046 shs

Market Capitalization

$58.22 billion

P/E Ratio

53.44

Dividend Yield

2.67%

Beta

N/A